Oral Nanomedicines for SiRNA Delivery to Treat Inflammatory Bowel Disease

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2022 Sep 23

PMID 36145716

Authors

Jongyoon Shinn

Juyeon Lee

Seon Ah Lee

Seon Ju Lee

Ah Hyun Choi

Jung Seo Kim

Su Jin Kim

Hyo Jin Kim

Cherin Lee

Yejin Kim

Joohyeon Kim

Jonghee Choi

Byungchae Jung

Taeho Kim

HyeonTaek Nam

Hyungjun Kim

Yonghyun Lee

Affiliations

Soon will be listed here.

Abstract

RNA interference (RNAi) therapies have significant potential for the treatment of inflammatory bowel diseases (IBD). Although administering small interfering RNA (siRNA) via an oral route is desirable, various hurdles including physicochemical, mucus, and cellular uptake barriers of the gastrointestinal tract (GIT) impede both the delivery of siRNA to the target site and the action of siRNA drugs at the target site. In this review, we first discuss various physicochemical and biological barriers in the GI tract. Furthermore, we present recent strategies and the progress of oral siRNA delivery strategies to treat IBD. Finally, we consider the challenges faced in the use of these strategies and future directions of oral siRNA delivery strategies.

Citing Articles

Attenuation of Chronic Inflammation in Intestinal Organoids with Graphene Oxide-Mediated Tumor Necrosis Factor-α_Small Interfering RNA Delivery.

Sakib S, Zou S Langmuir. 2024; .

PMID: 38325360 PMC: 10883062. DOI: 10.1021/acs.langmuir.3c02741.

Posttranscriptional Regulation of Intestinal Mucosal Growth and Adaptation by Noncoding RNAs in Critical Surgical Disorders.

Cairns C, Xiao L, Wang J J Invest Surg. 2024; 37(1):2308809.

PMID: 38323630 PMC: 11027105. DOI: 10.1080/08941939.2024.2308809.

References

Knipe J, Strong L, Peppas N . Enzyme- and pH-Responsive Microencapsulated Nanogels for Oral Delivery of siRNA to Induce TNF-α Knockdown in the Intestine. Biomacromolecules. 2016; 17(3):788-97. DOI: 10.1021/acs.biomac.5b01518. View

Pereira de Sousa I, Bernkop-Schnurch A . Pre-systemic metabolism of orally administered drugs and strategies to overcome it. J Control Release. 2014; 192:301-9. DOI: 10.1016/j.jconrel.2014.08.004. View

Forbes D, Peppas N . Oral delivery of small RNA and DNA. J Control Release. 2012; 162(2):438-45. DOI: 10.1016/j.jconrel.2012.06.037. View

Han Y, Gao Z, Chen L, Kang L, Huang W, Jin M . Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides/proteins. Acta Pharm Sin B. 2019; 9(5):902-922. PMC: 6804447. DOI: 10.1016/j.apsb.2019.01.004. View

Reinisch W, Sandborn W, Hommes D, DHaens G, Hanauer S, Schreiber S . Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011; 60(6):780-7. DOI: 10.1136/gut.2010.221127. View

Thornton D, Rousseau K, McGuckin M . Structure and function of the polymeric mucins in airways mucus. Annu Rev Physiol. 2007; 70:459-86. DOI: 10.1146/annurev.physiol.70.113006.100702. View

Roy K, Mao H, Huang S, Leong K . Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med. 1999; 5(4):387-91. DOI: 10.1038/7385. View

Loretz B, Foger F, Werle M, Bernkop-Schnurch A . Oral gene delivery: Strategies to improve stability of pDNA towards intestinal digestion. J Drug Target. 2006; 14(5):311-9. DOI: 10.1080/10611860600823766. View

Xiao B, Laroui H, Viennois E, Ayyadurai S, Charania M, Zhang Y . Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology. 2014; 146(5):1289-300.e1-19. PMC: 3992175. DOI: 10.1053/j.gastro.2014.01.056. View

10.

Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser G . Infliximab-Related Infusion Reactions: Systematic Review. J Crohns Colitis. 2015; 9(9):806-15. PMC: 4558633. DOI: 10.1093/ecco-jcc/jjv096. View

11.

Zhang S, Zhao B, Jiang H, Wang B, Ma B . Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release. 2007; 123(1):1-10. DOI: 10.1016/j.jconrel.2007.07.016. View

12.

Ming X, Sato K, Juliano R . Unconventional internalization mechanisms underlying functional delivery of antisense oligonucleotides via cationic lipoplexes and polyplexes. J Control Release. 2011; 153(1):83-92. PMC: 3133857. DOI: 10.1016/j.jconrel.2011.04.029. View

13.

Xiao B, Zhang Z, Viennois E, Kang Y, Zhang M, Han M . Combination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation. Theranostics. 2016; 6(12):2250-2266. PMC: 5135446. DOI: 10.7150/thno.15710. View

14.

Sandborn W, Feagan B, Marano C, Zhang H, Strauss R, Johanns J . Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2013; 146(1):85-95. DOI: 10.1053/j.gastro.2013.05.048. View

15.

Zhang M, Wang X, Han M, Collins J, Merlin D . Oral administration of ginger-derived nanolipids loaded with siRNA as a novel approach for efficient siRNA drug delivery to treat ulcerative colitis. Nanomedicine (Lond). 2017; 12(16):1927-1943. PMC: 5827822. DOI: 10.2217/nnm-2017-0196. View

16.

Lee Y, Sugihara K, Gillilland 3rd M, Jon S, Kamada N, Moon J . Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat Mater. 2019; 19(1):118-126. PMC: 6923573. DOI: 10.1038/s41563-019-0462-9. View

17.

Zhang J, Tang C, Yin C . Galactosylated trimethyl chitosan-cysteine nanoparticles loaded with Map4k4 siRNA for targeting activated macrophages. Biomaterials. 2013; 34(14):3667-77. DOI: 10.1016/j.biomaterials.2013.01.079. View

18.

Fox C, Kim J, Le L, Nemeth C, Chirra H, Desai T . Micro/nanofabricated platforms for oral drug delivery. J Control Release. 2015; 219:431-444. PMC: 4656086. DOI: 10.1016/j.jconrel.2015.07.033. View

19.

Ananthakrishnan A . Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015; 12(4):205-17. DOI: 10.1038/nrgastro.2015.34. View

20.

Citi S . Intestinal barriers protect against disease. Science. 2018; 359(6380):1097-1098. DOI: 10.1126/science.aat0835. View